Division of Urology, Brigham and Women's Hospital, 45 Francis Street, Boston, MA 02215, USA.
Department of Radiation Oncology, Dana Farber Cancer Institute/ Brigham and Women's Hospital, Boston, MA, USA.
Urol Clin North Am. 2023 May;50(2):325-334. doi: 10.1016/j.ucl.2023.01.008. Epub 2023 Feb 20.
Renal cell carcinoma (RCC) has historically been considered resistant to radiotherapy. However, advances in the field of radiation oncology have led to safe delivery of higher radiation doses through the use of stereotactic body radiotherapy (SBRT) that have shown significant activity against RCC. SBRT has now been shown to be a highly effective modality for management of localized RCC for nonsurgical candidates. Increasing evidence also points to a role for SBRT in the management of oligometastatic RCC as a means for not only providing palliation but prolonging time to progression and potentially improving survival.
肾细胞癌 (RCC) 历来被认为对放射治疗有抵抗力。然而，放射肿瘤学领域的进步通过使用立体定向体放射疗法 (SBRT) 实现了更安全地输送更高剂量的辐射，这对 RCC 具有显著的活性。现在已经证明 SBRT 是一种非常有效的局部 RCC 治疗方法，适用于不能手术的患者。越来越多的证据也表明 SBRT 在治疗寡转移 RCC 中的作用，不仅可以提供姑息治疗，还可以延长进展时间并有可能提高生存率。
